Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
- 
                
          Though limited to a large cohort2021-05-14  Though limited to a large cohort of self-reported healthy individuals, associations between individual mglur antagonist have been identified which may be clinically significant. Though slight, there is a relationship between the CYP2D6-inferred metabolizer phenotype and the diplotype-predicted activ 
- 
                
          Currently phosphodiesterase type PDE inhibitors are used wid2021-05-14  Currently, phosphodiesterase type 5 (PDE-5) inhibitors are used widely as the first- line oral treatment for erectile dysfunction of varying causes. Radical prostatectomy for the treatment of prostate cancer is frequently associated with erectile dysfunction, and this type of erectile dysfunction is 
- 
                
          Here although tibolone reduced the expression of inflammator2021-05-14  Here, although tibolone reduced the expression of inflammatory genes such as IL6, IL1β, TLR4 and MIR155-3p, in the presence of PA stimulation, it increased the expression of TNF gene. It should be noted that TNF has pleiotropic effects in the CNS, therefore its increased expression does not always i 
- 
                
          Grapiprant is a selective antagonist2021-05-14  Grapiprant () is a selective antagonist for prostaglandin E (PGE) receptor subtype 4 (EP4) identified as a clinical candidate for the treatment of inflammatory pain associated with osteoarthritis (OA). It is currently under development for use in humans and dogs. The projected dosing regimen of grap 
- 
                
          Clotrimazole receptor In vitro studies suggest that cPLA doe2021-05-14  In vitro studies suggest that cPLA2α does not show clear preference for the headgroup present at the sn-3 position, although a slight preference for zwitterionic phospholipids such as PC and PE has recently been pointed out [24]. In this regard, mass spectrometry analyses of glycerophospholipid hydr 
- 
                
          Elevation of plasma glucocorticoids as well as2021-05-13  Elevation of plasma glucocorticoids as well as a sympathetic activation are highly adaptive mechanisms allowing the individual to cope in various situations [39]. Novelty-induced increase in locomotor activity, characterizing the bold fish herein, accompanied by elevated glucocorticoids is a well-es 
- 
                
          br Results br Discussion C2021-05-13  Results Discussion C4 is related to another VACV protein, C16, and the C-terminal domain of C16 also inhibits DNA-PK-mediated DNA sensing via the same mechanism and to a similar level as C4. Moreover, mutagenesis of C16 at the CYC residues equivalent to those in C4 abrogated the C16-Ku interac 
- 
                
          In laboratory strains of Escherichia coli three2021-05-13  In laboratory strains of Escherichia coli, three mechanisms of repair for alkylated bases are known. The first involves constitutively expressed Ogt and inducible Ada methyltransferases, directly removing methyl groups from O6-methylguanine (O6meG) and O4-methylthymine (O4meT) [1], [2], [3], [4]. In 
- 
                
          In order to gain further insights into the role2021-05-13  In order to gain further insights into the role of peptidases in B. xylophilus, four cysteine proteases highly secreted by B. xylophilus (Cardoso et al., 2016) were selected four further characterisation. Materials and methods Results and discussion Structural prediction and analysis The i 
- 
                
          The present review also summarizes the2021-05-13  The present review also summarizes the efforts that have been made to find new c-FMS inhibitors under clinical trial as given in the Table 1. These inhibitors may reduce the burdens of potency and side effects that have faced the scientists globally. ABT-869 41 was manufactured in Abbott laboratorie 
- 
                
          br Material and methods br Results br Discussion2021-05-13  Material and methods Results Discussion In vitro evidence indicates that LAS191859 is a potent CRTh2 antagonist as demonstrated in GTPγS binding studies with potency in the low nanomolar range and in addition it demonstrates a long receptor residence time. This potency is also maintained in 
- 
                
          The pharmacokinetics properties of compound were2021-05-13  The pharmacokinetics properties of compound were evaluated in male Sprague Dawley rats following IV (0.7mg/kg) and oral (2.0mg/kg) dosing. The total body clearance and the terminal half-life were 0.73 L/h/kg and 5.1h, respectively. After oral administration the compound showed good bioavailability 
- 
                
          493 Another well established visceral action of2021-05-13  Another well-established visceral action of CRF and urocortin administered peripherally is the long-lasting lowering of blood pressure observed in various species ranging from rodents to humans [22]. Existing evidence suggests that the hypotensive action of CRF and urocortin is mediated by the inter 
- 
                
          The significant CRF increase in the2021-05-13  The significant CRF increase in the DS and the overall changes in the CRF system observed in the VM and DS during the development of sensitization suggest that this neuropeptide (and possibly urocortin) contributes to the specific molecular alterations occurring in the mesolimbic pathway that suppor 
- 
                
          CPG a metalloenzyme derived from sp was the elected2021-05-13  CPG2, a metalloenzyme derived from sp., was the elected enzyme for the first pilot-scale clinical trial of ADEPT. This enzyme has no mammalian homologue and activates glutamic Resminostat australia prodrug derivatives of several nitrogen mustards alkylating agents., , , , , A bond cleavable by CP 
16004 records 639/1067 page Previous Next First page 上5页 636637638639640 下5页 Last page